Brain tumors are complex ecosystems containing cells with heterogeneous genotypes and phenotypes, resulting in substantial cancer cell diversity. High-grade gliomas are particularly heterogeneous tumors and currently represent the most common cause of cancer-related death in children. Increasing evidence indicates that treatment failure and resistance are at least in part due to this heterogeneity. We used single-cell RNA sequencing (scRNA-seq) to profile the transcriptome of single cells in pediatric hemispheric high-grade glioma (histone wildtype) and diffuse intrinsic pontine glioma (DIPG; H3.3 K27M mutant) and reconstructed their cellular architecture. We found restricted expression of neural stem/progenitor expression programs in distinct subsets of cells, and observed that cellular programs evolve during genetic evolution. This suggests that both genetic and superimposed developmental programs contribute to tumor heterogeneity. These results provide an unparalleled insight into the cellular composition of pediatric high-grade gliomas and DIPGs at the level of single-cell resolution, and open up new avenues for discovering novel therapeutic targets.
. 2016 May 30;18(Suppl 3):iii74. doi: 10.1093/neuonc/now073.106
HG-110: SINGLE-CELL TRANSCRIPTOME ANALYSIS IN PEDIATRIC HEMISPHERIC AND MIDLINE HIGH-GRADE GLIOMAS
Mariella G Filbin
1,2, Itay Tirosh
2, Leah E Escalante
1,2, Andrew S Venteicher
1,2, Liliana Goumnerova
1,3, Kristine Pelton
1,3, Pratiti Bandopadhayay
1,2, Christopher Mount
4, Irene Slavc
5, Thomas Czech
5, Johannes Gojo
5, Cinzia Lavarino
6, Jaume Mora
6, Michelle Monje
4, Mark W Kieran
1,3, Keith L Ligon
1,3, Todd Golub
2,1, Aviv Regev
2, Mario L Suva
1,2
Mariella G Filbin
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
2Broad Institute, Cambridge, MA, USA
Find articles by Mariella G Filbin
Leah E Escalante
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
2Broad Institute, Cambridge, MA, USA
Find articles by Leah E Escalante
Andrew S Venteicher
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
2Broad Institute, Cambridge, MA, USA
Find articles by Andrew S Venteicher
Liliana Goumnerova
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
3Boston Children's Hospital, Boston, MA, USA
Find articles by Liliana Goumnerova
Kristine Pelton
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
3Boston Children's Hospital, Boston, MA, USA
Find articles by Kristine Pelton
Pratiti Bandopadhayay
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
2Broad Institute, Cambridge, MA, USA
Find articles by Pratiti Bandopadhayay
Cinzia Lavarino
6Hospital Sant Joan de Deu Barcelona, Barcelona, Spain
Find articles by Cinzia Lavarino
Mark W Kieran
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
3Boston Children's Hospital, Boston, MA, USA
Find articles by Mark W Kieran
Keith L Ligon
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
3Boston Children's Hospital, Boston, MA, USA
Find articles by Keith L Ligon
Todd Golub
2Broad Institute, Cambridge, MA, USA
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
Find articles by Todd Golub
Mario L Suva
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
2Broad Institute, Cambridge, MA, USA
Find articles by Mario L Suva
1Dana-Farber/Harvard Cancer Center, Boston, MA, USA
2Broad Institute, Cambridge, MA, USA
3Boston Children's Hospital, Boston, MA, USA
4Stanford University, Palo Alto, CA, USA
5Medical University of Vienna, Vienna, Austria
6Hospital Sant Joan de Deu Barcelona, Barcelona, Spain
Issue date 2016 Jun.
© the author(s) 2016. published by oxford university press on behalf of the society for neuro-oncology. all rights reserved. for permissions, please e-mail: journals.permissions@oup.com
PMCID: PMC4903369
